Synacthen Depot y Betametasona en el tratamiento del asma
Abstract
Se analiza que los resaltados obtenidos en el tratamiento de nuestros 175 casos con synacthen depoty betnasol,
fueron satisfactorios. Se establece que la corticoterapia sigue ocupando. Un lugar primordial en el
manejo de los enfermos afectados de asma bronquial. Se destaca que el uso de estos productos
requiere un chequeo clínico y radiológico pulmonar, para detectar cualquier portador oculto de T.
B., con el objeto de excluirlos del tratamiento, por los efectos secundarios que sobre esta
afección ellos determinan. Se concluye que los efectos secundarios encontrados en nuestros pacientes fueron mínimos, por lo que consideramos que el control de los enfermos y de la terapéutica hace inocuos a dichos medicamentos.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
